Six women developed rare blood clots after receiving the Johnson & Johnson vaccine, leading to general skepticism of J&J’s effectiveness.
The U.S. Center for Disease Control Prevention paused the distribution of J&J COVID-19 vaccines. Almost eight million Americans have gotten the Johnson & Johnson vaccine. Now, the agencies said they believes the shot’s benefits outweigh risks, according to EU drug regulators, and the temporary pause was lifted.
The single shot is being advised by the European Drug Administration as well as the U.S. Drug Administration to carry potential warning of risk of rare blood clots. The CDC and Food and Drug Administration deemed the J&J vaccine would carry a risk warning label. European regulators also resumed use of the J&J vaccine with warning labels.
University of Tampa student Bri Garrison received the J&J vaccine prior to the temporary pause of the vaccine.
“Six people out of millions have gotten the J&J vaccine, which is why I am not worried," Garrison said. "Something bad could happen with any vaccine, but the odds are extremely low.”
UC San Francisco infectious disease expert Monica Gandhi reported “all three vaccines – Johnson & Johnson, Pfizer, and Moderna – completely prevented hospitalizations and death in clinical trials.” After the FDA emergency pause on the J&J vaccine, the U.S. has three highly effective COVID-19 vaccines.
“In an ideal world, the vaccine would work for everyone, but we know it is not perfect," said Mass General nurse Patrcia Moran. "I believe that it was necessary to run more trials on the J&J vaccine. However, I am fully supportive of distributing this vaccine to my community.” Moran also stated she has multiple colleagues that received the J&J and had little worry about the effects.